InterMune, Inc.’s pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) has received “Fast Track” designation from the FDA. Fast Track designation is granted for drugs intended to treat a serious or life threatening condition that have the potential to address an unmet medical need. The FDA facilitates the development and expedites the review of applications for fast track products.     Dan Welch, chairman and chief executive officer of InterMune, said, &#8220...